Actinium Pharmaceuticals, Inc.
ATNM
$9.80
-$0.05-0.51%
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.45% | -15.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.93% | -27.36% | |||
| Operating Income | 7.21% | 27.93% | |||
| Income Before Tax | 7.01% | 29.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.01% | 29.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.01% | 29.77% | |||
| EBIT | 7.21% | 27.93% | |||
| EBITDA | 8.84% | 27.28% | |||
| EPS Basic | 8.53% | 30.72% | |||
| Normalized Basic EPS | 8.56% | 30.71% | |||
| EPS Diluted | 8.53% | 30.72% | |||
| Normalized Diluted EPS | 8.56% | 30.71% | |||
| Average Basic Shares Outstanding | 1.67% | 1.37% | |||
| Average Diluted Shares Outstanding | 1.67% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
